...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of surgical oncology >A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden
【24h】

A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden

机译：AJCC 7th和AJCC第8版的基于人口对瑞典患者患者的AJCC 7th和AJCC第8版的比较

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Cutaneous melanoma is steadily increasing worldwide. The new AJCC 8th edition was recently launched and introduced several changes in melanoma staging, particularly for stage III. We conducted a population-based registry study with the purpose to evaluate the impact and prognostic accuracy of the new classification in Sweden. Methods Consecutive patients diagnosed with stage III melanoma between January 2005 and September 2017 were identified by the Swedish Melanoma Registry (SMR) and included for analyses. Patients with multiple primary melanomas were excluded. Patients were classified according to the AJCC 7th as well as the 8th edition. Melanoma-specific survival (MSS) was retrieved from the Swedish Cause of Death Registry. Results A total of 2067 eligible patients were identified from the SMR; 1150 patients (57%) changed stage III subgroup when reclassified according to the AJCC 8th edition. The median 5- and 10-year MSS for the whole cohort of stage III melanoma patients was 59% and 51% respectively. The MSS for substage IIIA, B, and C were all improved when patients were reclassified by using to the AJCC 8th edition. The newly defined substage IIID had the worst prognosis with a 10-year MSS of 16%. Conclusions A high proportion of patients diagnosed with stage III melanoma in Sweden between 2005 and 2017 was restaged to another subgroup, when they were reclassified according to the AJCC 8th of staging manual. We established an improved MSS for all substages compared with the former AJCC 7th edition. This may have implications on decisions about adjuvant treatment.
机译：背景皮肤黑素瘤在全世界稳步增加。最近推出了新的AJCC第8版，并引入了黑色素瘤分期的几种变化，特别是III阶段。我们进行了一项以人口为基础的注册表研究，目的是评估瑞典新分类的影响和预后准确性。方法通过瑞典黑色素瘤注册管理机构（SMR）确定患有2005年1月至2017年9月至2017年9月至9月期间患有第三阶段黑素瘤的患者，并包括分析。患有多发性黑色素瘤的患者被排除在外。患者根据AJCC第7号以及第8版进行分类。从死亡登记处的瑞典原因取消了黑色素瘤的存活率（MSS）。结果共有2067名符合条件的患者均已从SMR中确定; 1150名患者（57％）根据AJCC第8版重新分类时改变了III阶段亚组。 III期阶段阶段群体的中位数5-和10年MSS分别为59％和51％。当患者通过使用到AJCC第8版倾斜时，物种IIIa，B和C的MSS全部得到改善。新定义的商品IIID具有最严重的预后，10年MS为16％。结论当2005年至2017年间瑞典患者患有第III期第III期黑色素瘤的患者的高比例均已根据分期手册的AJCC第8次重新分类。与前AJCC第7版相比，我们为所有商品建立了改进的MSS。这可能对关于佐剂治疗的决定产生影响。

著录项

  • 来源
    《Annals of surgical oncology》 |2019年第9期|共7页
  • 作者

    Isaksson Karolin; Katsarelias Dimitrios; Mikiver Rasmus; Carneiro Ana; Ny Lars; Bagge Roger Olofsson;

  • 作者单位

    Lund Univ Skane Univ Hosp Dept Clin Sci Lund Surg Lund Sweden;

    Univ Gothenburg Sahlgrenska Univ Hosp Inst Clin Sci Dept Surg Sahlgrenska Acad Gothenburg;

    Linkoping Univ Reg Canc Ctr South East Sweden Dept Clin &

    Expt Med Linkoping Sweden;

    Lund Univ Skane Univ Hosp Dept Clin Sci Lund Oncol Lund Sweden;

    Univ Gothenburg Sahlgrenska Univ Hosp Inst Clin Sci Dept Oncol Sahlgrenska Acad Gothenburg;

    Univ Gothenburg Sahlgrenska Univ Hosp Inst Clin Sci Dept Surg Sahlgrenska Acad Gothenburg;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 外科学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号